5 Saham Kesehatan Wanita Teratas (September 2026)

Separuh Populasi yang Diabaikan

Medicine has for very long been a male-dominated science and profession. This has led to women’s health issues being somewhat neglected. Even today, “Sekitar 1% penelitian perawatan kesehatan diinvestasikan pada kondisi spesifik perempuan di luar onkologi”, dan “Kondisi Kesehatan Wanita di luar onkologi mencakup kurang dari 2% dari pipeline perawatan kesehatan saat ini”.

Selain itu, tubuh wanita agak lebih kompleks dibandingkan pria, dengan pola hormon, organ, dll. Jadi, apa yang berhasil untuk pria belum tentu berhasil untuk wanita.

Dan ada banyak kebutuhan akan alat, obat, dan peralatan khusus, seperti mammogram, obat kesuburan, perawatan menopause, dll. Dan ada perusahaan yang berspesialisasi untuk memenuhi permintaan tersebut.

Sektor kesehatan wanita bernilai $38 Miliar pada 2021 dan kembali tumbuh setelah penurunan ringan selama pandemi. Diperkirakan akan tumbuh dengan CAGR sehat 4,9 % hingga 2030.

Sumber: Polaris Market Research

Sektor ini juga menarik perhatian korporasi “big pharma” (Bayer, Pfizer (PFE ), dll.) dengan serangkaian akuisisi atau kesepakatan lisensi dalam beberapa tahun terakhir.

5 Saham Kesehatan Wanita Teratas

1. Hologic, Inc.

By far the largest women’s health company by market capitalization, partially because it is also active in the diagnostic sector in general. Still, the core of the company market is women’s diagnostics, including skeletal health and scanner systems, and a lot of the diagnostic products are related to STIs (Sexually Transmitted Infections).

Sumber: Hologic

Dalam peralatan, kesehatan payudara merupakan segmen penting, mencakup semua kebutuhan medis seperti skrining & radiologi, operasi, evaluasi jaringan (untuk kanker), dan pemulihan.

Produk inti perusahaan tumbuh kembali setelah penurunan selama pandemi, sekaligus mendapat pendapatan tambahan dari tes Covid selama pandemi, yang kini menurun.

Sumber: Hologic

Kebanyakan pendapatan berasal dari diagnostik dan bersifat consumable, sehingga menjadi pembelian berulang dari laboratorium analisis dan rumah sakit. Peralatan yang dibeli selama pandemi, seperti platform analisis molekuler Panthe, kini digunakan untuk analisis lain, dengan 85 % pelanggan baru menjalankan setidaknya satu assay selain tes Covid.

Hologic menguntungkan dan menghasilkan $5 Miliar arus kas bebas dalam 3 tahun terakhir (seperempat kapitalisasi pasar). Dari arus kas bebas ini, $1,4 Miliar digunakan untuk akuisisi (6 kesepakatan) dan $1,7 Miliar untuk pembelian kembali saham. Perusahaan juga melunasi hutangnya sehingga net debt hanya $0,3 Miliar, turun dari puncak $4 Miliar pada 2013.

Hologic is a good women’s health stock pick for investors looking for a financially solid, growing, profitable, and well-established company. Its healthy cash flows also allow it to be a serial acquirer and gather a growing portfolio of women-focused medical treatment and testing technology.

2. Evofem Biosciences, Inc.

As a side note, Evofem melakukan reverse stock split 1-125, yang menjelaskan grafik harga saham yang agak aneh.

Evofem adalah penjual Phexxi, metode kontrasepsi revolusioner tanpa hormon yang disetujui pada musim panas 2020. Produk ini dikembangkan dengan dukungan University of Illinois Chicago. Hal ini membuatnya banyak diadopsi oleh wanita yang sebelumnya tidak ingin atau tidak dapat menggunakan bentuk kontrasepsi lain (sering karena alasan medis).

Metode ini menggunakan kombinasi asam laktat, asam sitrat, dan kalium bitarat, serta memberikan perlindungan terhadap klamidia dan gonore. Produk ini juga relatif sederhana dan murah untuk diproduksi.

Karena Phexxi memengaruhi pH vagina, ia juga berpotensi memiliki aplikasi lain, khususnya pada Bacterial Vaginosis (BV). Fase 2 uji klinis untuk aplikasi ini kini siap. Ia juga dapat digabungkan dengan obat lain untuk menciptakan Multipurpose Prevention Technology (MPT), sebuah strategi yang dieksplorasi bersama Orion Biotechnology.

Total pasar kontrasepsi AS bernilai $8,3 Miliar, dan Phexxi masuk dalam kategori kontrasepsi yang ditanggung oleh sebagian besar rencana kesehatan, sehingga tidak menimbulkan biaya bagi wanita, menurut klarifikasi hak akses kontrasepsi AS Januari 2023.

Penjualan Phexxi meningkat pesat sejak disetujui, mencerminkan kesadaran dan adopsi wanita yang semakin tinggi terhadap solusi ini. Pertumbuhan berlanjut pada 2023, dengan Februari 2023 mencatat 15 % lebih banyak unit terjual dibandingkan Februari 2022.

Sumber: Evofem

Selain meningkatkan pendapatan, Evofem bekerja menurunkan biaya, hanya $25 Juta pada Q3 2022 dibandingkan $45 Juta pada Q3 2021.

Perusahaan menargetkan mencapai break-even arus kas pada 2023 dan meluncurkan kembali di bursa utama (saham saat ini diperdagangkan melalui bursa Over-the-Counter (OTC)).

Dengan paten Phexxi berlaku setidaknya hingga 2033, ini merupakan perusahaan niche produk tunggal yang menarik dengan runway IP yang panjang. Pertumbuhan masa depan dapat berasal dari aplikasi tambahan (BV, MPT) dan lisensi internasional.

Investors will want to keep an eye on the cash flow improvement and the future cash redistribution policy. A potential acquisition by a larger company could be possible as well. The potential for entry of imitators or new competitors should also be factored in.

3. Daré Bioscience, Inc.

DARE Grafik Harga

The company is focusing its research efforts along a few axes, with some of the key R&D efforts being:

• Contraception.
  • Phase 3 of clinical trials initiated in mid-2023 for the 1st Hormone-free, Monthly Contraceptive in joint development with Bayer.
• Vaginal health.
  • First commercial in Q2 2023 for a  bacterial vaginosis treatment: XACIATO.
• Reproductive & sexual health + Menopause.
  • Phase 2b of the trial for a topical cream with the same active ingredient as Viagra®
• Fertility.

Sumber: Dare BiosciencesThe company-approved product, XACIATO, allowed Daré to collect a first $10M payment from Organon (OGN), the spin-off from Merck with a partial focus on women’s health (around 1/3 of its sales). Organon will license the global rights for XACIATO since Juni 2022, with up to $182.5M in further milestone payments and double-digit royalties based on net sales.

The most advanced clinical trial, the monthly contraceptive Ovaprene with Bayer, could bring up to $310M to Daré.

It is a little soon to know XACIATO’s future cash flow to Daré Bioscience, and Ovaprene still needs to pass the phase 3 trials. So, this is more of a stock for investors willing to take the risk of an early-stage startup, with the lower risk of at least one product already approved by the FDA and some solid partnership for the products in development.

4. Aspira Women’s Health Inc.

Aspira is focused on ovarian cancer. The company developed OvaSuite, a blood test for ovarian cancer, to use in combination with ultrasound checkups (OvaWATCH). It tests the risk of ovarian cancer and can help determine the risks and profile of the cancer as well (Ova1Plus).

Sumber: Aspira

OvaWatch was launched in November 2022 and in 2023 got integrated into the coverage of a large national payer with 80 million people now covered for OvaWatch.

The company market is the 1+ million women diagnosed with adnexal masses (masses on the ovaries) yearly. Only 10% of the 200,000 surgeries in the US following this diagnosis are actual cancer, leading to unnecessary costs ($20,000/surgery), suffering, and serious consequences like infertility, early menopause, etc…

Sumber: Aspira

The problem of actually identifying the cancer is compounded by the risk of biopsies spreading the cancer. So, liquid biopsies, using blood tests, are a much superior diagnostic option. (You can read more about other liquid biopsy companies in our article “Best Early Cancer Detection And Liquid Biopsy Stocks (Mei 2023)”).

If they reach 50% of the potential market, OvaWatch would be $225M to $281M in revenues, and Ova1Plus $38M-$56M. Expansion of the technology for monitoring could bring the revenue potential to $500M. Since 2021, revenues, margins, and sales volume have all grown by 18-23%.

Sumber: Aspira

Aspira is at an interesting point for investors looking for an approved product that markets might not have fully priced in, as it is a very under-covered niche. Not only women’s health but a very technical diagnostic for a specific cancer, which mostly brings an improved diagnosis. It’s not the most straightforward topic for most investors. It is nevertheless a considerable medical advancement and might translate into growing revenues and cash flow in the next few years.

5. Minerva Surgical, Inc.

UTRS Grafik Harga

Minerva Surgical describes itself as “The Uterine Health Company.” The company was founded to improve the treatment of Abnormal uterine bleeding (AUB). This can affect 1 out of 3 women over their life and can cause complications.

Poor care of AUB leads to unnecessary hysterectomies (ablation of the uterus), with 68% of the 400,000 hysterectomies done for benign conditions like AUB, fibroids, or endometriosis.

These unneeded hysterectomies significantly increase the risk of serious health problems, including heart failure and coronary artery disease.

Sumber: Minerva Surgical

In 2020, they acquired three additional devices for the treatment of AUB to create a full intra-uterine care kit.

The kit provides better care, direct visualization, and fewer doctor visits.

Sumber: Minerva Surgical

In Q1 2023, the company brought $12.5M in revenues, an increase of 15% from the $10.9M in Q1 2022. Operating expenses were $17.3M in Q1 2023, R&D costs $5.3M, and net loss $11.3M.

The company also did a private placement of $30M in  Februari 2023., led by Accelmed, a $630M private equity firm specializing in investing in medical devices and technology.

Minerva is a company delivering a valuable product, still at an early stage of its commercial adoption. Changing the medical practices in women’s health is a rather difficult task. At the same time, the recent private placement put the company out of any short-term risk regarding liquidity and solubility.

So, this is a stock ideal for investors willing to bet that the current market capitalization does not reflect the long-term prospect of the company to change the treatment of AUB from routine use of hysterectomies to “softer” surgeries using Minerva devices.